Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial  by Carbone, David P. et al.
1653Journal of Thoracic Oncology  •  Volume 7, Number 11, November 2012
Introduction: We investigated the predictive and prognostic effects 
of VeriStrat, a serum or plasma-based assay, on response and survival 
in a subset of patients enrolled on the NCIC Clinical Trials Group, 
BR.21 phase III trial of erlotinib versus placebo in previously treated 
advanced non–small-cell lung cancer patients.
Methods: Pretreatment plasma samples were available for 441 of 
731 enrolled patients and were provided as anonymized aliquots to 
Biodesix. The VeriStrat test was performed in a Clinical Laboratory 
Improvement Act-accredited laboratory at Biodesix, Inc. (Boulder, 
CO). The results (Good, Poor) were returned to NCIC Clinical Trials 
Group, which performed all the statistical analyses.
Results: VeriStrat testing was successful in 436 samples (98.9%), 
with 61% classified as Good. VeriStrat was prognostic for overall sur-
vival in both erlotinib-treated patients and those on placebo, indepen-
dent of clinical covariates. For VeriStrat Good patients, the median 
survival was 10.5 months on erlotinib versus 6.6 months for placebo 
(hazard ratio 0.63, 95% confidence interval 0.47–0.85, p = 0.002). For 
VeriStrat Poor patients, the median survival was 4 months for patients 
receiving erlotinib, and 3.1 months for placebo (hazard ratio: 0.77, 
95% confidence interval 0.55–1.06, p = 0.11). VeriStrat was predic-
tive for objective response (p = 0.002), but was not able to predict 
for differential survival benefit from erlotinib (interaction p = 0.48). 
Similar results were found for progression-free survival. 
Conclusion: We were able to confirm that VeriStrat is predictive of 
objective response to erlotinib. VeriStrat is prognostic for both OS 
and progression-free survival, independent of clinical features, but is 
not predictive of differential survival benefit versus placebo.
Key Words: Erlotinib, Proteomics, Metastatic Non–small-cell lung 
cancer, Biomarkers.
(J Thorac Oncol. 2012;7: 1653–1660)
BR.21 was a randomized placebo-controlled study of erlo-tinib in previously treated patients with advanced non–
small cell lung cancer (NSCLC). The overall response rate 
was 8.9% in the erlotinib arm compared with less than 1% for 
placebo, and both progression-free survival (PFS) and overall 
survival (OS) were prolonged by erlotinib.1 Correlative stud-
ies performed in patients with available tissue showed that epi-
dermal growth factor receptor (EGFR) protein expression, the 
presence of activating EGFR mutations, and high EGFR copy 
number were predictive of response. EGFR mutations were 
prognostic for OS, but were not predictive, whereas increased 
EGFR copy number was both prognostic and predictive for 
OS benefit.2,3 Tumor tissue was not available in all patients, 
highlighting the need for less-invasive predictive tests such 
as serum or plasma biomarkers. A recent exploratory study 
on plasma samples from BR.21 reported amphiregulin as a 
prognostic marker and transforming growth factor-α as a bio-
marker predictive of OS benefit from erlotinib4; these obser-
vations remain to be validated in prospective clinical trials.
VeriStrat is a commercially available serum- or plasma-
based test using matrix-assisted laser desorption ionization 
(MALDI) mass spectrometry methods. Veristrat analysis 
was conducted by Biodesix (Boulder, CO) in their CLIA-
accredited laboratory. It was developed using a training set of 
pretreatment serum samples from patients who experienced 
long-term stable disease or early progression on gefitinib 
therapy.5 Mass spectra from serum samples of these patients 
were used to define eight mass spectra features (i.e., peaks), 
differentiating these two outcome groups. An algorithm, using 
these features and based on a k-nearest neighbors classifica-
tion scheme, was created and its parameters were optimized 
using additional spectra from the training cohort. The current 
commercial test uses a fixed set of parameters established dur-
ing the development phase. VeriStrat assigns each spectrum a 
binary classification of Good or Poor. Validation studies were 
performed in a blinded fashion using multiple single-arm 
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cohorts of patients undergoing EGFR tyrosine kinase inhibi-
tor (TKI) therapy. Two independent cohorts of patients who 
were treated with gefitinib or erlotinib confirmed that patients 
classified as Good had better outcomes than patients classified 
as Poor (hazard ratio [HR] of death 0.47, p = 0.009 and HR 
of death 0.33, p = 0.0007).5 In other control cohorts, VeriStrat 
status did not correlate significantly with clinical outcome 
after chemotherapy (HR 0.74, p = 0.42 and HR 0.81, p = 0.54) 
or in the postsurgery setting (HR 0.90, p = 0.79).5 On the basis 
of these results, it was postulated that VeriStrat might be a 
predictive marker specifically for EGFR TKI therapy.
The primary goal of the current study was to test 
VeriStrat’s ability to predict response and survival benefit 
(PFS and OS) from erlotinib, using pretreatment plasma sam-
ples from BR.21.
PATIENTS AND METHODS
Patients and Plasma Samples
In BR.21, 731 patients were randomized (2:1 ratio) to 
receive erlotinib or placebo. The clinical trial database resides 
at NCIC Clinical Trials Group. Full details of the methodol-
ogy have been published previously.1 Blood samples were col-
lected from consenting patients for pharmacokinetic assays 
and for banking and stored at the Tumor Tissue Repository of 
the NCIC CTG, Kingston, Ontario. Patients provided sepa-
rate written consent for this optional tissue banking. Baseline 
pretreatment samples from consenting patients were anony-
mized, using a unique ID, aliquoted, and provided to Dr. David 
Carbone for analyses. No clinical data were sent. The Research 
Ethics Board at Vanderbilt University approved this study.
VeriStrat Analysis
VeriStrat analysis was conducted on 441 available 
plasma samples by Biodesix (Broomfield, CO). Samples were 
thawed on wet ice and aliquots diluted 1:10 in HPLC-grade 
water (Burdick & Jackson, Muskegon, MI), then combined 
with an equal volume of sinapinic acid (Sigma, St. Louis, 
MO) solution (25 mg/ml sinapinic acid prepared in 50% 
acetonitrile[Burdick & Jackson]/0.1% trifluoroacetic acid 
[Sigma]). Each sample-matrix mixture was spotted in trip-
licate at randomly assigned positions on polished stainless 
steel MALDI plates (BrukerDaltonics, Bremen, Germany). 
Positive ion mass spectra for all samples and replicates were 
acquired in linear mode, using the BrukerAutoflex III mass 
spectrometer. Averaged spectra, consisting of 2000 indepen-
dent spectrum acquisitions, from each sample replicate were 
used for processing and classification. Spectral processing 
included background and noise estimation, background sub-
traction, normalization to partial ion current, and alignment. 
The classification algorithm, a k-nearest neighbor classifier, 
based on eight distinct m/z features,5 was applied to the aver-
aged, processed spectra. A VeriStrat label of Good or Poor 
was produced for each sample when all replicates from a sam-
ple gave the same classification. When replicates from a 
sample gave discordant classifications, an indeterminate label 
was assigned. Results were sent to NCIC CTG where they 
were merged with the clinical trial database.
Statistical Analysis
A statistical analysis plan was agreed before any analyses 
being conducted. Exploratory analyses were performed to char-
acterize the relationship between VeriStrat status and baseline 
characteristics and outcomes. Chi-square tests or Fisher’s exact 
tests were used to assess the association between categorical 
variables; the Kaplan–Meier product limit method and the log-
rank test were used to estimate and compare the distributions 
of time-to-event outcomes. A Cox regression model with inter-
action terms included was used to verify VeriStrat’s prognos-
tic and predictive effect on the primary endpoint of OS while 
adjusting for other baseline factors, including sex, age (≤60 
years versus >60 years), Eastern Cooperative Oncology Group 
performance status (0,1 versus 2,3), pathologic subtype (adeno-
carcinoma versus squamous versus others), response to prior 
therapy (complete response/partial response versus progres-
sive disease versus stable disease), number of prior regimens (1 
versus 2/3), prior platinum, EGFR expression by immunohis-
tochemistry (IHC) (positive versus negative versus unknown), 
race (Asian versus other), EGFR gene mutation status (exon 19 
or 21 versus not mutated + other mutation versus unknown), 
time from diagnosis to randomization (<12 months versus 
≥ 12 months), weight loss (< 5% versus ≥ 5%), smoking status 
(nonsmoker versus ever smoked versus unknown) and EGFR 
fluorescence in-situ hybridization (FISH) status: (high copy/
amplified [FISH+] versus low copy [FISH−] versus unknown). 
Prognostic analyses were performed on patients enrolled to the 
placebo arm only. Statistical analyses were carried out using 
SAS Version 9.1 (SAS Institute, Cary, NC). All reported p values 
are two sided and levels of significance taken to 0.05.
RESULTS
VeriStrat
Of 441 plasma samples available, 436 (98.9%) could 
be classified as Good or Poor. Table S1 summarizes the base-
line factors for patients with evaluable results (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A335). The eval-
uable cohort had significantly more male patients (p = 0.03) 
and derived better OS benefit from erlotinib (HR 0.67, 95%CI 
0.54–0.83, p=0.0003, Fig. 1) compared with the nonevalu-
able cohort (HR 0.93, 95%CI 0.73–1.22, p = 0.61). In the Cox 
regression model the test of interaction was 0.06. The reason 
for the differential benefit is unclear.
Baseline characteristics for evaluable patients classified 
as Good and Poor are summarized in Table S2 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A335). Patients 
classified as Good were more likely to have characteris-
tics usually associated with better prognosis: female sex 
(p = 0.02), Asian race (p = 0.005), good performance status 
(p < 0.0001), adenocarcinoma (p < 0.0001) and weight 
loss <5% (p < 0.0001). There was no significant correlation 
between classification and smoking status or response to prior 
chemotherapy. Although there was a correlation between 
classification and EGFR IHC status, as in previous studies6,7 
no significant correlations were found with EGFR or KRAS 
mutation status, or EGFR gene copy number. Although the 
differences were not significant most patients who had EGFR 
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exon 19 or 21 mutations were in the Good cohort (71%) as 
were lifetime nonsmokers (65%).
Prognostic Properties of VeriStrat
OS for the 144 placebo patients is shown in Figure 2. 
VeriStrat was prognostic with Good patients (median survival 
6.6 months, 95% CI 4.4–8.2) surviving significantly longer 
than Poor patients (3.1 months, 95%CI 2.2–3.7; HR 0.44, 
95% CI 0.31–0.63, p < 0.0001). VeriStrat remained prognostic 
(p = 0.05) in multivariate analysis (Table 1). Similar results 
were obtained for PFS (data not shown); HR Good versus 
Poor 0.59 (95% CI 0.42–0.83, p = 0.0016) in both univariate 
and multivariate (p = 0.001) analyses (Table 1).
Predictive Properties of VeriStrat on Survival
The interaction term comparing relative benefit in the 
two cohorts was not significant (p = 0.48), indicating that both 
the Good and Poor cohorts derived similar relative benefit 
from erlotinib. Median survival was 10.5 months for Good 
patients treated with erlotinib versus 6.6 months for those on 
placebo (HR 0.63, 95% CI 0.47–0.85; p = 0.002) (Fig. 3A 
and B) whereas in the Poor cohort, the median survival for 
erlotinib was 3.98 months and 3.09 months for placebo (HR 
0.77, 95%CI 0.55–1.06, p = 0.11). Similar results were found 
in multivariate analyses (Table 2) adjusted for potential con-
founding factors and other predictive markers with a nonsig-
nificant interaction test (p = 0.50). In unplanned exploratory 
analyses EGFR copy number (FISH +) was predictive of erlo-
tinib benefit (p = 0.05).
Similar results were seen for PFS (Fig. 3C and D). Both 
Good and Poor patients had significant PFS benefit from treat-
ment (p = 0.0000 and 0.05, respectively, interaction p = 0.36). 
In multivariate adjusted analyses, the interaction p value again 
was not significant (Table 2).
Predictive Properties of VeriStrat for Objective  
Response
Response data for patients on the erlotinib arm8 are sum-
marized in Table 3. Of 252 erlotinib-treated patients evaluable 
for response, 157 (62%) were classified as Good and 95 (38%) 
as Poor. Good patients had a significantly higher response rate 
than Poor patients did (11.5% versus 1.1%, p = 0.002) , with 
a Good classification remaining independently significantly 
correlated with response after adjustment for potential con-
founding factors (Table S3).
Exploratory Subgroup Analyses
In analyses of patients without detected activating EGFR 
mutations (exon 19 deletion or exon 21 L858R) and patients 
without adenocarcinoma histology, there was no significant 
interaction, indicating no evidence of differential benefit for 
either subgroup (p = 0.51 and 0.73, respectively). The median 
OS for Good patients was 10.5 versus 6.3 months (HR 0.63 
in patients without detected activating EGFR mutation, p = 
FIGURE 1. Kaplan–Meier plots of OS for patients A, with or B, without available plasma.
FIGURE 2. Prognostic Analysis: Kaplan–Meier plots of OS.
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0.004) and 10.5 versus 5.8 months (HR 0.60 for nonadenocar-
cinoma p = 0.02), and for Poor patients, 4.0 versus 3.1 months 
(HR 0.78 in patients without detected activating EGFR muta-
tion, p = 0.13) and 4.9 versus 3.1 months (HR 0.71 nonadeno-
carcinoma, p = 0.11).
DISCUSSION
Biomarker-based selection of patients for specific tar-
geted therapies is becoming a standard of care.9,10 One exam-
ple of this is patients whose tumors carry activating EGFR  
mutations.11,12 The Iressa Pan-Asia Study trial (gefitinib 
versus carboplatin/paclitaxel as first-line treatment for pul-
monary adenocarcinoma among an Asian population of nev-
ersmokers or former light smokers) clearly demonstrated the 
superiority of gefitinib versus chemotherapy in terms of PFS 
and response rate (although not OS), for those with EGFR 
mutation-positive tumors.13,14 The results of trials performed 
after at least second-line treatment also confirmed the predic-
tive effect of EGFR mutations on tumor response and PFS; 
however, the predictive effect of mutations on OS remains 
unclear, as patients with EGFR mutant tumors seem to sur-
vive longer regardless of therapy. Although this is usually 
attributed to the effects of postprogression crossover to TKI 
treatment, trials of unselected patients have demonstrated 
survival benefit in patients without such mutations.15 An anal-
ysis of BR.21 showed that EGFR mutations and high EGFR 
copy number are predictive of response to erlotinib, but muta-
tion status was not predictive of OS benefit compared with 
patients with wild-type EGFR tumors, although the number of 
patients with mutations probably was too low to demonstrate 
significant quantitative interaction.3 The Iressa Non-small 
Cell Lung Cancer Trial Evaluating Response and Survival 
against Taxotere, a randomized study comparing second-line 
treatment with docetaxel or gefitinib, also showed the predic-
tive role of EGFR mutations in response and PFS to gefitinib, 
whereas no measured biomarker was predictive of differential 
survival benefit.10,16 Interestingly, the Sequential Tarceva in 
Unresectable NSCLC trial of maintenance erlotinib showed 
statistically significant OS benefit only in patients without 
EGFR mutations,17 and in BR.19, where unselected patients 
were randomized to gefitinib versus placebo as postoperative 
adjuvant therapy, there was no survival benefit in the overall 
study population, nor in patients with EGFR mutated tumors.18
Activating EGFR mutations are present in approxi-
mately 30% to 40% of Asian patients, but only 5% to 15% 
in whites.19,20 Although large-scale mutation screening is fea-
sible,21 sample collection and successful mutation analysis in 
most large multisite clinical trials typically have been low, 
(20%–30%). This may be because of many factors including 
scanty tissue from cytology diagnostic slides, tissue-quality 
requirements for the biomarker assay, and the capacity and 
infrastructure of the investigational site.22 In recent publica-
tions, it has been highlighted that although DNA sequence 
abnormalities may seem to be very readily and reliably mea-
sured, in practice the observed discordance of mutation sta-
tus assessment is highly dependent on sample quality and the 
method of analysis, and can reach 30%. This may affect the 
outcome of treatment.23 Thus, the presence of EGFR muta-
tions, although now widely accepted as the basis for choosing 
an EGFR-TKI for frontline therapy of advanced NSCLC, does 
not identify the entire population of NSCLC patients who may 
benefit from these drugs. Especially useful would be biomark-
ers that can be measured using samples obtained by noninva-
sive procedures in every patient.
As a blood-based test, VeriStrat, is reproducible, readily 
available, and has the potential to overcome the difficulties of 
obtaining fresh biopsy tissue from patients. In published stud-
ies using samples from patients not enrolled in randomized 
controlled trials, it was suggested that VeriStrat might be pre-
dictive of EGFR inhibitor benefit even in a population of smok-
ers and in those with squamous carcinoma.5 Further studies in 
other tumor types also reported different survival outcomes in 
VeriStrat Good and Poor subsets that was independent of the 
specific anti-EGFR agents used.7 In squamous cell carcinoma 
of the head and neck, VeriStrat Good designation was associ-
ated with longer survival in patients treated with gefitinib (HR 
Good versus Poor 0.41, p = 0.007) and in studies of patients 
treated with erlotinib/bevacizumab (HR 0.2, p = 0.02), and 
cetuximab (HR 0.26, p = 0.06). The patients in these analyses 
were not part of randomized trials with control arms that did 
not include EGFR therapy; however, two chemotherapy-only 
cohorts of lung cancer patients,5 a chemotherapy-only cohort 
TABLE 1. Multivariate Prognostic Analyses of OS and PFS for 
the Placebo Arm
Variable
OS PFS
Hazard Ratio  
(95% CI) p-Value
Hazard Ratio  
(95% CI) p-Value
VeriStrat
Poor 1 1
Good 0.67 (0.45–1.01) 0.05 0.56 (0.40–0.80) 0.001
PS
0,1 1
2,3 1.77 (1.14–2.76) 0.01
Histology
Adenocarcinoma 1
Squamous 1.71 (1.11–2.63) 0.015
Other 0.80 (0.45–1.24) 0.25
Weight Loss
Less than 5% 1
5% or more 2.03 (1.31–3.15) 0.0015
Unknown 0.60 (0.23–1.56) 0.29
FISH
FISH- 1 1
FISH+ 2.23 (1.03–4.83) 0.04 2.01 (1.04–2.23) 0.04
Unknown 1.51 (0.84–2.70) 0.17 1.58 (0.93–2.66) 0.09
Time from diagnosis to randomization
≤ 12 months 1
> 12 months 0.50 (0.34–0.74) 0.0005
Sex
Female 1
Male 1.52 (1.04–2.23) 0.03
Missing items indicate that a variable was not significant and so was not used in 
the analysis.
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of squamous cell carcinoma of the head and neck patients,7 
and a surgery-only cohort of lung cancer patients5 showed no 
statistically significant survival difference when classified by 
the VeriStrat test. In another cohort study of colorectal cancer 
patients treated with cetuximab, PFS was significantly longer 
for Good compared with Poor patients (HR 0.51, p = 0.0065).7 
In a study of NSCLC patients treated second-line with a com-
bination of erlotinib and bevacizumab, patients classified as 
Poor were shown to have extremely poor OS and PFS24 com-
pared with those classified as Good (HR 0.14, p = 0.007 and 
HR 0.045, p = 0.0003 for OS and PFS, respectively). Similar 
results were obtained in a first-line study of the same combi-
nation of targeted treatments in nonsquamous NSCLC, which 
reported a median PFS of 16.5 weeks in Good patients and 9.3 
weeks in Poor patients and median OS of 79.1 weeks in Good 
patients and 12.5 weeks in Poor patients.25 A study of NSCLC 
patients treated with first-line erlotinib and sorafenib found an 
HR of 0.30 (95% CI 0.12–0.74; p = 0.009) for OS and 0.40 
(95% CI 0.17–0.94, p = 0.035) for PFS between Good and 
Poor patients.26
Because of the absence of randomization to control 
arms that did not include EGFR therapy in the above studies, 
it was not possible assess whether the VeriStrat test identified 
two cohorts of patients with different prognoses or whether 
it truly was predictive of better outcome from EGFR inhibi-
tor therapy. In all three of the chemotherapy-only and surgical 
studies, VeriStrat Good patients experienced longer survival 
than Poor patients. Although the differences in survival were 
not significant, these studies may have provided the first hint 
that VeriStrat might be a prognostic test.
Our study evaluated both the prognostic and predictive 
value of VeriStrat. Of 731 patients enrolled on BR.21, plasma 
samples from 441 were available for testing and it was pos-
sible to classify 99% of patients into Good and Poor cohorts. 
We were able to confirm that VeriStrat was predictive of 
response. However, for both OS and PFS, VeriStrat was prog-
nostic, but was not predictive of differential benefit from erlo-
tinib. In exploratory analyses, although significant correlation 
was detected between VeriStrat and EGFR protein expression 
determined by IHC, no significant correlations were found 
FIGURE 3. Kaplan–Meier plots of OS by treatment arm for A, VeriStrat Good patients and B, VeriStrat Poor patients. Kaplan–
Meier plots of PFS by treatment arm for C, VeriStrat Good patients and D, VeriStrat Poor patients
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with other measured biomarkers, including EGFR or KRAS 
mutation status, and EGFR FISH status, confirming results 
from previous studies.6,7
There are several limitations to our study. Although 
plasma collection was planned prospectively in the original 
clinical trial, this assay and the analyses were not. Although 
sample size estimations taken before our analyses suggested 
sufficient power to test the hypothesis, the sample size of 
the clinical trial was based on clinical outcomes, and not all 
patients consented to the storage of plasma, leading to a non-
random subset of patients in this study. Indeed, there were dif-
ferences in baseline clinical characteristics and outcomes in 
patients with and without plasma samples,4 a common prob-
lem of retrospective biomarker studies on subsets of the trial 
population.27
Although our results confirm a predictive effect of 
VeriStrat for response, they do not confirm a predictive effect 
for VeriStrat on OS or PFS. VeriStrat did seem to identify a 
subset of previously treated patients who experienced a sur-
vival benefit that may be considered more clinically meaning-
ful than that seen in VeriStrat Poor patients in whom survival 
TABLE 2.  Multivariate Predictive Analyses of OS and PFS for the Patients with Evaluable Blood Samples
Variable
OS PFS
Hazard Ratio (95% CI) p-Value Hazard Ratio (95% CI) p-Value
Treatment
Placebo 1 1
Erlotinib 0.98 (0.51–1.90) 0.96 1.40 (0.75–2.61) 0.29
VeriStrat
Poor 1 1
Good 0.52 (0.35–0.76) <0.0006 0.71 (0.50–1.02) 0.06
Treatment × VeriStrat 
interaction
0.86 (0.55–1.34) 0.50 0.77 (0.51–1.18) 0.23
PS
0,1 1
2,3 1.62 (1.27–2.06) 0.0001
Smoking status
Ever smoker 1 1
Never smoker 0.59 (0.44–0.78) 0.0003 0.72 (0.56–0.93) 0.01
Unknown 0.73 (0.45–1.17) 0.19 0.82 (0.53–1.28) 0.38
Weight loss
<5% 1 1
5% or more 1.63 (1.27–2.09) 0.0001 1.44 (1.14–1.82) 0.0025
Unknown 0.59 (0.31–1.13) 0.11 0.90 (0.52–1.55) 0.70
FISH
FISH- 1 1
FISH+ 1.64 (0.82–3.28) 0.16 2.48 (1.27–4.83) 0.008
Unknown 1.30 (0.75–2.23) 0.35 1.70 (1.01–2.88) 0.047
Treatment × FISH+ 0.39 (0.15–0.99) 0.05 0.22 (0.09–0.54) 0.0009
Treatment × FISH 
unknown
0.75 (0.38–1.47) 0.40 0.51 (0.27–0.96) 0.04
Time from diagnosis to randomization
≤12 months 1 1
>12 months 0.69 (0.55–0.86) 0.0009 0.82 (0.67–1.00) 0.05
Prior regimen
1 1
2+ 1.25 (1.01–1.55) 0.04
Missing items indicate that a variable was not significant and so was not used in the analysis.
TABLE 3.  Objective Responses in Erlotinib-Treated Patients 
by VeriStrat Status
VeriStrat 
Good
VeriStrat 
Poor
Total
Patients evaluable for response 157 95 252
Patients not evaluable for response 26 14 40
PD/SD (%) 139 (89%) 94 (99%) 233 (92%)
PR/CR (%) 18 (11%) 1 (1%) 19 (8%)
PD, progressive disease; SD, stable disease; PR, partial response; CR, complete 
response.
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was short. Alternatives to erlotinib may be considered for 
these patients. More information should become available 
from the Randomized Proteomic Stratified Phase III Study of 
Second-line erlotinib versus Chemotherapy in Patients with 
Inoperable Non–Small-Cell Lung Cancer currently accruing, 
which will compare erlotinib with chemotherapy in patient 
cohorts stratified according to VeriStrat classification.
The nature, origin, and potential direct biological sig-
nificance of the detected protein biomarkers is as yet not 
completely clear. As biomarker studies developing classi-
fiers from large protein or RNA expression data sets essen-
tially are correlative in nature, conclusions about cause and 
effect between the measured biomarkers and the measured 
outcomes frequently are impossible. Despite these consider-
ations, efforts have been made to identify the proteins con-
stituting the measured features. Several of the peaks seem to 
contain isoforms of serum amyloid A, but several remain to 
be identified. However, patients classified as Poor have not yet 
been seen in our studies of inflammatory diseases associated 
with high serum amyloid A levels, such as rheumatoid arthri-
tis or chronic obstructive pulmonary disease. As the VeriStrat 
Poor classification has now been identified in many epithelial 
cancer types, including breast, renal, colorectal, melanoma, 
upper gastrointestinal, and head and neck, but not in healthy 
patients, and because the mechanism of MALDI mass spec-
trometry makes it easiest to detect high-to-mid-range abun-
dance proteins, it is possible that VeriStrat is detecting a 
tumor–host response to the presence of the cancer.
Recently, in exploratory hypothesis generating analyses, 
the EGFR ligand TGF-α was shown to be predictive of ben-
efit from erlotinib versus placebo in this same patient popu-
lation.4 High baseline transforming growth factor (TGF)-α 
(present approximately 10 % of study patients) predicted 
lack of benefit from erlotinib compared with low TGF-alpha 
(TGF-alpha low, OS HR 0.66; 95% CI 0.54–0.81; p = 0.0001; 
high, OS HR 1.32; 95% CI 0.73–2.39; p = 0.36; interaction 
p = 0.04). Baseline TGF-α was not prognostic or predictive for 
PFS. In the same study, amphiregulin, another EGFR ligand, 
was found to be prognostic, but not predictive of a differen-
tial survival benefit from erlotinib. However, this study did not 
have separate training and testing cohorts, and thus the results 
require independent confirmation.
In summary, VeriStrat is able to predict response 
to erlotinib and is a prognostic biomarker in previously 
treated patients with advanced NSCLC. Further studies are 
required to define the clinical utility of VeriStrat and other 
blood-based biomarkers in defining the appropriate patient 
population for therapy with erlotinib and other EGFR-based 
therapeutics.
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